Status:
COMPLETED
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborating Sponsors:
Innovive Pharmaceuticals
Conditions:
Leukemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether the WT-1 vaccine causes an immune response and is safe. The WT-1 vaccine is made up of protein pieces that the patient's immune system can recognize a...
Detailed Description
Design: This will be a pilot trial evaluating the safety and immunogenicity of the WT-1 peptide vaccine in patients with hematologic malignancies. Ten patients with acute myelogenous leukemia (AML) o...
Eligibility Criteria
Inclusion
- Cytologic or histologic diagnosis of acute myelogenous leukemia or myelodysplastic syndrome confirmed at Moffitt Cancer Center.
- Patients with acute myelogenous leukemia will have completed induction chemotherapy, achieved first complete remission (CR) 1 or 2, and will have completed any planned postremission therapy (at discretion of treating physician),with no plan for allogenic or autologous transplant.
- Patients with myelodysplastic syndrome who according to the International Prognostic Scoring System (IPSS) are category Int-2 or greater, with disease that relapsed, progressed, or not responded to at least 1 prior course of approved therapy for MDS (i.e. hypomethylating agent or lenalidomide).
- Patients with AML/MDS must have documented WT-1 + disease. For purposes of this study, this may be either the demonstration of WT-1 protein on a pretreatment bone marrow biopsy or detectable disease with RQ-PCR. For patients in whom a bone marrow aspirate is not available or possible (e.g. "dry tap"), a peripheral blood sample may be used for WT-1 screening. In such cases, 10 cc of peripheral blood will be collected in a heparinized tube.
- At least 4 weeks must have elapsed between the patient's last chemotherapy or radiation treatment and the first vaccination.
- Karnofsky performance status ≥ 70%
- Hematologic parameters:
- Absolute neutrophil count ≥ 1000/mcL (except for MDS, for which the parameter is ≥ 500/mcL)
- Platelets \> 50 K/mcL (except for MDS for which the parameter is \> 25 K/mcL and not transfusion dependent)
- Biochemical parameters:
- Total bilirubin ≤ 2.0 mg/dl
- Aspartic transaminase (AST) and Alanine transaminase (ALT) ≤ 2.5 x upper limits of normal
- Creatinine ≤ 2.0 mg/dl
Exclusion
- Pregnant or lactating women
- Patients with leptomeningeal disease
- Patients with active infection requiring systemic antibiotics, antiviral, or antifungal treatments
- Patients with serious unstable medical illness
- Patients taking systemic corticosteroids
- Patients with central nervous system (CNS) involvement with cancer/leukemia
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00665002
Start Date
June 1 2008
End Date
February 1 2015
Last Update
February 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612